Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05528952
Title Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma (TERTIO)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Centre Hospitalier Universitaire de Besancon
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.